Statera Biopharma, Inc. / Fundamentals
Income statement
- Net revenue
€3.18M - Cost of goods sold
€945.70K - Gross profit
€2.24M - SG&A expenses
€10.84M - R&D expenses
€8.63M - EBITDA
-€72.28M - D&A
€479.87K - EBIT
-€76.08M - Interest expenses
€9.70M - EBT
-€79.24M - Tax expenses
€3.87M - Net income
-€82.31M
Cash flow statement
- Net deferred tax
€58.31M - Non-cash items
-€2.29M - Changes in working capital
€11.47M - Operating cash flow
-€11.09M - Capex
€89.16K - Other investing cash flow
-€7.12K - Net investing cash flow
-€89.16K - Total cash dividends paid
€0.00 - Issuance of common stock
€7.00M - Debt repayment
-€8.28M - Other financing cash flow
€613.86K - Net financing cash flow
-€713.98K - Foreign exchange effects
€70.25K - Net change in cash
-€11.83M - Cash at end of period
€436.55K - Free cash flow
-€11.00M
Balance sheet
- Cash and cash equivalents
€436.55K - Cash and short-term investments
€436.55K - Total receivables
€311.77K - Inventory
€91.12K - Other current assets
€298.43K - Total current assets
€1.05M - Property, plant & equipment
€880.39K - Goodwill
€7.99M - Intangible assets
€1.07M - Long-term investments
€0.00 - Other non-current assets
€0.00 - Total non-current assets
€9.94M - Total assets
€11.00M - Accounts payable
€7.01M - Short-term debt
€5.80M - Other current liabilities
€6.03M - Total current liabilities
€19.18M - Long-term debt
€591.86K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€591.86K - Total liabilities
€19.77M - Common stock
€218.86K - Retained earnings
-€124.28M - Other equity
€46.32K - Total equity
-€8.77M - Total liabilities and shareholders' equity
€11.00M
Company information
- Market capitalization
€6.09K - Employees
46 - Enterprise Value
€14.42M
Company ratios
- Gross margin
-
70.3% Much better than peer group: -208.9% - EBITDA margin
-
-2,272.2% Much better than peer group: -5,796.6% - EBIT margin
-
-2,391.7% Much better than peer group: -6,082.0% - EBT margin
-
-2,490.9% Much worse than peer group: -1,085.4% - Net margin
-
-2,587.7% Much better than peer group: -1,993,714.8% - ROE
-
938.5% Much worse than peer group: 98,510.7% - ROA
-
-748.5% Much better than peer group: -865,066.7% - Asset turnover
-
28.9% Worse than peer group: 47.2% - FCF margin
-
-351.6% Much better than peer group: -6,642.9% - FCF yield
-183,568.6% - Efficiency ratio
2,372.2% - Net sales per employee
-
€69.15K - Net income per employee
-
-€1.79M